https://www.selleckchem.com/pr....oducts/chk2-inhibito
This study aimed to investigate whether fear of progression mediates the association between illness perception and quality of life among interstitial lung disease patients. So far, the physiological treatment of interstitial lung disease is limited. In addition to immunosuppressants such as glucocorticoids, two anti-fibrosis drugs (pirfenidone and nintedanib) have shown moderately beneficial effects on slowing the progression of interstitial lung disease fibrosis. However, none of these drugs has shown reliable or stro
Aimer
Commentaire
Partagez
